Bio TiumBio expedites immunotherapy TU2218 trials in US, Korea TiumBio, a Korean biotech firm, is speeding up clinical trials of TU2218, investigational immunotherapy, in the U.S. and Korea.In the U.S., the Kosdaq-listed company is testing TU2... Kim Chan

Press/Media: Press / Media

Period2022 Mar 15

Media coverage

1

Media coverage

  • TitleBio TiumBio expedites immunotherapy TU2218 trials in US, Korea TiumBio, a Korean biotech firm, is speeding up clinical trials of TU2218, investigational immunotherapy, in the U.S. and Korea.In the U.S., the Kosdaq-listed company is testing TU2... Kim Chan
    Media name/outletKorea Biomedical Review
    Date22/3/15
    URLct.moreover.com/?a=47273532815&p=1gw&v=1&x=xOthcBgG7N3bVdfiEqqH3g
    PersonsSoon-Il An